1) Why Semaglutide Became So Important

For a long time, the topic of "weight" was reduced to two words: calories and exercise. But science gradually showed something deeper: appetite is not just a desire, but biology. The body regulates hunger and satiety through hormones, nerve signals, and brain mechanisms.

Semaglutide emerged as a molecule that acts precisely on this biological system. Therefore, its effect is not "motivating" but physiological – with proper application, it can change how a person perceives hunger, satiety, and the "noise" around food.

The data and facts in the article are synthesized from regulatory and clinical information described in the analytical report on semaglutide. 

2) The Hormone That Controls Hunger

After eating, the intestines release a series of hormones that "explain" to the body what is happening. One of the most important is GLP-1 (Glucagon-Like Peptide-1).

GLP-1 does several things simultaneously: it stimulates insulin release when glucose is high, suppresses glucagon, slows stomach emptying, and sends signals to the brain that we are full. The problem is that natural GLP-1 is short-lived – it degrades quickly.

And here's the idea: if we have a molecule that works like GLP-1 but stays in the body longer, we can maintain these effects steadily, not just for minutes.

3) What Is Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist – meaning it activates the same receptor that natural GLP-1 activates. The molecule is a peptide analog with high homology to human GLP-1 and has been modified to bind to albumin and have an approximate one-week half-life with subcutaneous administration. 

4) How It Works in the Body

Blood Sugar Control – Smart, Glucose-Dependent

Semaglutide stimulates insulin and suppresses glucagon in a glucose-dependent manner. This is crucial because it explains why the risk of hypoglycemia is usually lower when not combined with medications like insulin or sulfonylureas. 

Appetite and Brain – Silence in the "Food Channel"

GLP-1 receptors are also present in the brain – in the appetite centers. When activated, appetite decreases, satiety increases, and "intrusive thoughts about food" in many people noticeably diminish.

Stomach – Slower Rate, Longer Satiety

Semaglutide slows gastric emptying, especially in the early phase after eating. This helps for a smoother glucose profile and a longer feeling of satiety. 

"It's not magic. It's physiology – appetite is a signaling system. Semaglutide just recalibrates it."

5) What Is the Effect on Weight

The most cited data for weight reduction come from large clinical programs in people with overweight/obesity. In STEP-1 (semaglutide + lifestyle), the average change in weight reached approximately −14.9% over 68 weeks, compared to −2.4% with placebo. 

This is a huge difference compared to classic "diet and exercise only" approaches in people who are already in metabolic stagnation. And it's important to state clearly here: these results are from a controlled clinical context, with titration and medical supervision.

6) Cardiovascular Benefits

Semaglutide is interesting not only because of weight. In the large SELECT study in people with established cardiovascular disease, BMI ≥ 27, and without diabetes, a reduction in major cardiovascular events (heart attack/stroke/CV death) with an HR of approximately 0.80 was observed, which is interpreted as an approximately 20% relative risk reduction. 

This positions semaglutide as a molecule that is not "cosmetics for kilos" but part of a larger idea: metabolic health is directly linked to longevity and vascular risk.

7) Liver (MASH) and Why This Is a Big Topic

Metabolic-associated steatohepatitis (MASH) is a serious progressive condition – not just "fatty liver," but inflammation and damage that can lead to fibrosis. Data in the regulatory context (US) show significant histological improvements in certain populations, emphasizing that some approvals are fast-tracked and confirmatory data for long-term clinical endpoints are awaited.  

The lifestyle conclusion is simple: when you improve appetite, glycemia, and weight, the liver is often among the first organs to "breathe." But this does not negate the need for medical evaluation and follow-up, because MASH is a diagnosis, not just a feeling.

8) Kidneys and Metabolic Protection

In type 2 diabetes and chronic kidney disease, semaglutide is associated with a reduction in the risk of adverse renal outcomes, including a sustained decline in eGFR and progression to end-stage kidney disease, with the label/regulatory formulation noting that the mechanism of renal protection is not fully established. 

Practically, this means: it's not just about "fewer kilos," but about a systemic effect on the risk profile in metabolically ill patients.

9) How It's Administered and What "Titration" Means

Semaglutide exists in injectable and oral forms. The injectable form is usually administered once a week, and oral variants have specific instructions for intake because oral bioavailability is low and highly dependent on intake conditions (fasting, little water, interval to food). 

"Titration" means gradually increasing the dose. The reason is simple: the most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). Slower titration often improves tolerability.

10) Side Effects and How to Think About Them

The most common adverse reactions are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain. In clinical programs for higher doses for weight, these reactions are common and are the main reason some people discontinue therapy. 

There are also more serious risks that should not be "underestimated": pancreatitis, cholelithiasis, complications in diabetic retinopathy, as well as the risk of dehydration with severe vomiting/diarrhea (which can worsen kidney function). 

11) Contraindications and Important Limitations

Semaglutide has clearly defined warnings and contraindications in regulatory documents, including a contraindication for a personal/family history of medullary thyroid carcinoma (MTC) or MEN2 (especially emphasized in the US context). 

Pregnancy: due to the long half-life and potential risk, therapy is discontinued sufficiently before planned pregnancy (labels indicate an interval of several months). 

12) What Happens Upon Discontinuation

One of the most important truths, rarely spoken "aloud": for many people, some of the weight returns after discontinuation. Data from clinical observations show significant weight regain upon discontinuation after a period of treatment. 

The lifestyle translation is clear: if therapy was the only strategy, return is logical. If therapy was a "bridge" to new habits (protein, strength training, sleep, daily activity, better choices), the chance of maintenance is higher.

13) The New Era in Metabolic Medicine

Semaglutide and GLP-1 therapies have changed the narrative: obesity is increasingly seen as a chronic metabolic condition where the brain, gut, pancreas, and hormones are involved in "setting" hunger and energy expenditure.

This does not negate discipline. It simply puts it in a smarter framework: discipline = system. And the system includes biology.

Source of scientific claims: analytical report on semaglutide, based on regulatory labels and large clinical programs. 

Semaglutide vs Tirzepatide vs Retatrutide – which is more effective

Following the success of semaglutide, pharmaceutical companies began developing a new generation of metabolic therapies that act on more hormonal receptors simultaneously. This led to the emergence of two new molecules – tirzepatide and retatrutide.

The three drugs belong to the group of so-called incretin therapies, but there are important differences in their mechanism of action.

Semaglutide

Semaglutide is a GLP-1 receptor agonist. This means it mimics the action of the hormone GLP-1 and leads to:

• reduced appetite
• slowing of stomach emptying
• improved blood sugar control
• significant weight loss

In large clinical trials, weight loss reached approximately 15% of body mass.

Tirzepatide

Tirzepatide is a newer molecule that activates two receptors simultaneously – GLP-1 and GIP.

This dual activation leads to an even stronger metabolic effect. In clinical trials SURMOUNT, patients lost an average of 20–22% of their body weight.

Therefore, tirzepatide is often described as second-generation GLP-1 therapy.

Retatrutide

Retatrutide is an even newer experimental molecule that activates three receptors simultaneously:

• GLP-1
• GIP
• glucagon

This triple-combined mechanism leads to a very strong effect on metabolism and energy expenditure.

In early clinical trials, patients lost up to 24% of their body weight, a result comparable to some bariatric surgeries.

Which is most effective

If we compare the three therapies in terms of weight loss efficacy, the approximate picture looks like this:

• Semaglutide – about 15%
• Tirzepatide – about 20–22%
• Retatrutide – up to 24%

It is important to understand, however, that these results come from different clinical studies and populations. Furthermore, retatrutide is still in clinical development and is not widely available.

For this reason, semaglutide remains one of the most studied and proven therapies for metabolic health at present.

Ozempic Face – what it means and why it appears

One of the most discussed effects of semaglutide therapy is the so-called "Ozempic face".

This term is not a medical diagnosis. It is used in the media to describe changes in facial appearance in people who lose a significant amount of weight in a relatively short period.

What happens to the face

When a person loses weight rapidly, especially with a loss of more than 10–15% of body weight, the amount of subcutaneous fat in the face also decreases.

This can lead to:

• more pronounced cheekbones
• hollowing around the eyes
• looser skin
• more visible wrinkles

It is important to emphasize that this is not a specific side effect of the drug. The same changes are observed in people who lose significant weight through diet or bariatric surgery.

How can this effect be reduced

There are several strategies that can help for a more balanced body transformation:

• slower weight loss
• high protein intake
• strength training
• good sleep and hydration

These factors help preserve muscle mass and maintain better facial and body structure.

Other potential side effects

In addition to the stomach complaints already mentioned, other adverse reactions may occur in some patients.

• gallstone disease
• pancreatitis
• dehydration
• problems with diabetic retinopathy

Therefore, semaglutide therapy should always be monitored by a medical professional.